Journal of Clinical Oncology
Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma.
Journal of Clinical Oncology
Gene expression signature associated with in vitro dexamethasone resistance and post-induction minimal residual disease in pediatric T-cell acute lymphoblastic leukemia.
Journal of Clinical Oncology
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.
Journal of Clinical Oncology
Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.
Journal of Clinical Oncology
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).
Journal of Clinical Oncology
Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis.
Journal of Clinical Oncology
Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis.
Journal of Clinical Oncology
Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis.
Journal of Clinical Oncology
In Reply.
Journal of Clinical Oncology